vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• vTv Therapeutics has a consensus “Moderate Buy” rating from nine analysts: six buys, one strong buy, one hold, and one sell. The average 12-month price target is $55.83.
• Analysts have recently raised their outlook, including BTIG increasing its price target to $57 and Rodman & Renshaw setting a $67 target, while other firms issued mixed rating changes.
• Shares opened at $30.03, well below the analyst consensus target, but the company recently reported a quarterly loss of $1.05 per share, missing estimates by $0.08; analysts expect a full-year loss of $2.35 per share.

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $55.83.

Several equities research analysts have issued reports on VTVT shares. Wall Street Zen raised shares of vTv Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Lifesci Capital raised shares of vTv Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 2nd. BTIG Research boosted their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. Rodman & Renshaw assumed coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They set a "buy" rating and a $67.00 price objective for the company. Finally, Weiss Ratings downgraded shares of vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th.

vTv Therapeutics Price Performance

Shares of VTVT stock opened at $30.03 on Wednesday. The company has a market cap of $118.32 million, a price-to-earnings ratio of -28.33 and a beta of 0.21. The stock has a 50 day simple moving average of $32.10 and a 200-day simple moving average of $33.78. vTv Therapeutics has a 1-year low of $19.50 and a 1-year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.08). Analysts anticipate that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc NASDAQ: VTVT is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company's research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer's disease.

vTv's development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.